Browse All
Displaying 151 - 155 of 274
Author:Meca Lallana, Jose Eichau Madueno, Sara Casanova, Bonaventura Alvarez Rodríguez, Elena Pato, Antonio Toledo, Baldo Forner, Mireia
Session Name:P7: MS Therapeutics 1
Topic:MS and Inflammatory Disease
Program Number:P7.018
Author Institution:Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, Murcia, Spain Hospital Virgen Macarena, Sevilla, Spain, Sevilla, Spain Hospital Universitari I Politécnic La Fe, Valencia, Spain, Valencia, Spain Hospital Álvaro Cunqueiro, Vigo, Spain , Vigo, Spain Hospital Povisa, Vigo, Spain, Vigo, Spain Sanofi, Barcelona, Spain, Barcelona, Spain
Author:Bowen, James Stulc, Jessica Hunter, Samuel Antezana, Ariel Chen, Hailu Lewin, James Scaramozza, Matthew Bozin, Ivan Then Bergh, Florian
Session Name:P8: MS Therapeutics 2
Program Number:P8.001
Author Institution:Swedish Neuroscience Institute, Seattle, WA Minneapolis Clinic of Neurology, Golden Valley, MN Advanced Neurosciences Institute, Franklin, TN Neuromedical Clinic of Central Louisiana, Alexandria, LA Biogen Inc., Cambridge, MA University of Leipzig, Klinik u. Poliklinik fuer Neurologie, Leipzig, Germany
Author:Alvarez, Enrique Hersh, Carrie Robertson, Derrick Das Gupta, Ayan Hu, Xixi Zielman, Ronald Boer, Ibolya Cheadle, Andy Cohen, Jeffrey
Program Number:P8.002
Author Institution:Department of Neurology, Rocky Mountain Multiple Sclerosis Center at the University of Colorado , Aurora, CO Lou Ruvo Center for Brain Health, Cleveland Clinic Mellen Program for MS, Las Vegas, NV Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL Novartis Healthcare, Hyderabad, India Novartis Pharmaceuticals Corporation, East Hanover, NJ Novartis Pharma B.V., Amsterdam, Netherlands Novartis Pharma AG, Basel, Switzerland Department of Neurology, Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH
Author:Kieseier, Bernd Cenni, Bruno Pulz, Robert Angst, Daniela Eichlisberger, Denis Ziehn, Marina
Program Number:P8.003
Author Institution:Novartis Pharma AG Novartis Institutes for Biomedical Research
Author:Cohen, Jeffrey Hauser, Stephen Cross, Anne Winthrop, Kevin Wiendl, Heinz Nicholas, Jacqueline Meuth, Sven Giacomini, Paul Sacca, Francesco Zielman, Ronald Das Gupta, Ayan Hu, Xixi Sullivan, Roseanne DeLasHeras, Virginia Kappos, Ludwig
Program Number:P8.004
Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA Washington University School of Medicine, Saint Louis, MO, USA, Clayton, MO Public Health and Preventive Medicine, Division of Infectious Diseases, Oregon Health and Sciences University, Portland, OR, USA, Portland, OR University of Muenster, Muenster, Germany, Muenster, Germany OhioHealth Multiple Sclerosis Center, Columbus, OH, USA, Columbus, OH Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany, Duesseldorf, Germany Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada, Montreal, QC, Canada NSRO Department, University “Federico II” of Naples, Naples, Italy, Napoli, Italy Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Morristown, NJ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland
